key: cord-0817824-1xojla8n authors: Zouaghi, Oualid; Wintzer-Wehekind, Jérôme; Lienhart, Yves; Abdellaoui, Mohamed; Faurie, Benjamin title: Ambulatory TAVR: early feasibility experience during Covid-19 pandemic date: 2020-08-21 journal: CJC Open DOI: 10.1016/j.cjco.2020.08.005 sha: 4e880b8ab2c19fa8fc987d59ab9528998cad2b59 doc_id: 817824 cord_uid: 1xojla8n The COVID-19 pandemic has modified practice for patients with symptomatic aortic stenosis and could result in higher mortality due to treatment delays. In this clinical case series, three patients underwent ambulatory transcatheter aortic valve replacement (TAVR) thanks to patient and entourage willingness, careful patient selection (including a prior history of permanent pacemaker) and a minimalist procedural approach. No complications occurred during the 30-day follow-up. Performing ambulatory TAVR could reduce the clinical consequences of wait times, minimize exposure to coronavirus contamination and reduce the use of hospital resources that might be needed for COVID-19 patients. The COVID-19 pandemic has modified practice for patients with symptomatic aortic stenosis and could result in higher mortality due to treatment delays. In this clinical case series, three patients underwent ambulatory transcatheter aortic valve replacement (TAVR) thanks to patient and entourage willingness, careful patient selection (including a prior history of permanent pacemaker) and a minimalist procedural approach. No complications occurred during the 30-day follow-up. Performing ambulatory TAVR could reduce the clinical consequences of wait times, minimize exposure to coronavirus contamination and reduce the use of hospital resources that might be needed for COVID-19 patients. Thanks to a scrupulous minimalist TAVR protocol, ambulatory outpatient management of aortic stenosis was possible in the context of the Covid-19 pandemic. We report a case series of patients undergoing ambulatory transcatheter aortic valve replacement thanks to a careful patient selection (including a prior history of permanent pacemaker) and a minimalist procedural approach. This strategy could reduce the clinical consequences of wait times, minimize exposure to coronavirus contamination and reduce the use of hospital resources that might be needed for COVID-19 patients. The availability of limited beds to handle the large volume of coronary and valve interventions promotes outpatient practice, which is even more appealing with the COVID-19 pandemic. This strategy has been proven to be safe and efficient for PCI, while only one case of same-day discharge after successful TAVR has been described. 1 The purpose of this study was to report, for the first time, a small series of outpatients TAVR procedures and to provide a protocol to facilitate patient selection for safe and fully ambulatory aortic stenosis care. An 86 year old man with chronic obstructive pulmonary disease and a permanent pacemaker implanted 6 months earlier for AV block was admitted for ambulatory TAVR. This elective transfemoral TAVR procedure was performed under local anesthesia and optimized by a new virtual reality google system from DEEPSEN ® (Saint-Didier-au-Mont-d'or, France) which involves a hypnosis and cardiac coherence algorithm with a 360-cinema screen ( Figure 1A) . Only 1 mg of Midazolam was given at the beginning of the procedure, with an anesthesiologist providing close patient supervision throughout. During any painful steps of the procedure (punctures, valve deployment), specific analgesia was provided through the google system by sending additional visual and auditory signals. Transfemoral vascular access was performed after loco-regional block, using an echo-guided puncture technique and a percutaneous suture-based closure device. No central venous access was needed. A 5 French pigtail catheter was introduced via the left dorsal distal radial artery ( Figure 1A ). Using a left ventricular Safari 2 XS ® supportive guidewire, a 26mm Edwards Sapien valve ® was implanted without predilatation ( Figure 1B) . Cardiac standstill was obtained with direct wire pacing (DWP) at 160 beats/min for 15 seconds avoiding the need for temporary right ventricular access and potential complications. The procedure was uneventful. Right femoral closure was assessed by selective right iliofemoral angiogram and confirmed complete hemostasis without complications. Total procedural time was 43 minutes with 160 ml of contrast media and 47 Gy/cm2 of dose surface area. The patient was transferred to the post procedure care unit where he underwent an iliofemoral doppler and a transthoracic echocardiography (TTE), which revealed a mean gradient of 4 mm Hg, an aortic valve area of 1.9 cm2, and no intra or paravalvular leak. Telemetry was unremarkable and ambulation was possible and well tolerated 3 hours after the femoral closure. Because the patient met strict criteria for an ambulatory TAVR strategy including no cognitive impairment, adequate social and family support, a prior pacemaker, no post procedural complication, and given that he was previously planned and informed for such an approach, he was home-discharge 6 hours after the procedure. A nurse visited him on day 1 and day 7 for clinical follow-up and he was seen in the outpatient clinic 1-month later. No adverse events were noticed. To date, three ambulatory TAVR cases have been performed in our institution without complications in the 30-days post procedure. Baseline characteristics of each patient are described in Supplementary Table S1 . This is, to our knowledge, the first-time report of a small case series of outpatient TAVR procedures. It is of particularly interest in the current context of the COVID-19 pandemic which has generated increased pressure on health care systems around the world. Ambulatory TAVR, in well selected patients and using a minimalist approach, 2 could be a safe option in order to (i) reduce the clinical consequences of wait times for TAVR (several studies have shown higher mortality among patients with severe symptomatic AS with a delay in treatment), 3 (ii) minimize potential exposure to coronavirus in patients at particularly high risk for clinical deterioration, and (iii) reduce the use of hospital resources that might be needed for COVID-19 patients. 4 In our institution, ambulatory TAVR is offered to patients with selective baseline characteristics, procedural and postprocedural requirements as listed in Supplementary Table S2 Limitations include the small number of cases performed to date, and restrictive patient selection criteria. Based on the national French registry, about 15% of patients undergoing TAVR have a prior permanent pacemaker. 5 This is an important limitation for increased use of ambulatory TAVR procedures. Moreover, this ambulatory strategy could be associated with delayed complications such as vascular access bleeding emphasizing the need for careful post procedural monitoring. • COVID-19 pandemic has generated a deleterious delay in the management of patients with aortic stenosis • Ambulatory TAVR is safe in well selected patient • A minimalist Approach is mandatory to allow the same day discharge Same day discharge after transcatheter aortic valve replacement: Are we there yet? A less-invasive totally-endovascular (LITE) technique for trans-femoral transcatheter aortic valve replacement Temporal Trends and Clinical Consequences of Wait Times for Transcatheter Aortic Valve Replacement: A Population-Based Study Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement Analysis of length of stay after transfemoral transcatheter aortic valve replacement: results from the FRANCE TAVI registry All authors report no disclosures.